Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

NEW YORK, Oct. 14, 2021…

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

NEW YORK, Sept. 30, 2021…

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Immunic and the University Medical…

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Immunic, Inc. Announces Closing of…

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc. Announces FDA Clearance…

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Immunic and 4SC AG Sign…

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces Positive Top-Line…

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immunic, Inc. Announces That Oral…

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immunic, Inc. Added to NASDAQ…

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immunic, Inc. Announces 200 Patients…